ClinicalTrials.gg
RecruitingNCT05835310BLOSSOMUpdated Sep 30, 2026

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

A Phase 3 interventional study of Anifrolumab and Placebo in Systemic Lupus Erythematosus, sponsored by AstraZeneca. Recruiting at 103 sites in 17 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Sep 30, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Planned enrollment
11th of 20
100 · median 159
Started
2024
the only one that year
Phase 3
9 of 20
4 open now
Primary completion
2028-10
later than 6 of 10 live
Registered
13th of 20
by date
Lead sponsor
15 of 20
AstraZeneca

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 11th largest by planned enrollment, is the only one that started in 2024, is one of 9 in phase 3, reaches primary completion later than 6 of the 10 other live ones, and was the 13th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

Read the detailed description

This study aims to characterize the pharmacokinetics, pharmacodynamics, efficacy, and safety of anifrolumab solution for infusion compared with placebo solution for infusion in pediatric participants with severe active systemic lupus erythematosus who are on background standard of care therapy.

The study duration for a participant will be approximately 116 weeks, which includes:

  • Screening period of up to 30 days.
  • Part A consists of a four-week, double-blind, placebo-controlled, randomised, pharmacokinetic period.
  • Part B is a double-blind, placebo-controlled, randomised, safety/efficacy period lasting 48 weeks (for rollover participants from Part A) or 52 weeks (for de novo participants).
  • Part C is a 52-week open-label extension period.
  • Part D is a safety follow-up period. One safety visit at 12 weeks post last dose.
03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic Lupus Erythematosus
  • SLE
  • Monoclonal Antibody
  • Anifrolumab
  • Parallel-group treatment
  • Pediatric participants
  • Standard of care therapy
  • Intravenous
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant's parent/caregiver/legally authorized representative and participant (if required per local country regulation) capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Informed assent is to be provided by the participant per local country regulation.
  • Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) criteria for at least 3 months prior to signing the ICF.
  • At Screening, participant must have moderate to severe active SLE disease, as adjudicated by the Central Adjudication Committee, defined as:

    (a) SLEDAI-2K activity of: (i) ≥ 6 points with at least 4 points (≥ 4 points) coming from the following clinical components ('Clinical' SLEDAI-2K score): arthritis, myositis, rash, alopecia, mucosal ulcers, pleurisy, pericarditis, or vasculitis and excluding points attributed to a fever, SLE headache, and organic brain syndrome (ii) Clinical SLEDAI score of ≥ 4 points verified at Day 1 (b) BILAG-2004 activity of: (i) ≥ 1 BILAG A score; or (ii) ≥ 2 BILAG B scores (c) PGA score ≥ 1.0 on a 0 to 3 VAS

  • Participant should meet all of following tuberculosis (TB) criteria:

A. No signs or symptoms of active TB B. No medical history or past physical examinations suggestive of active TB C. No recent contact with a person with active TB or if there has been such contact, referral to a TB specialist for evaluation and initiation of treatment for latent TB, if warranted, prior to the first administration of study intervention in accordance with local SoC D. No history of latent TB without documented completion of treatment prior to initial screening visit

  • Female participants of must have a negative serum pregnancy test at screening and negative urine pregnancy test at randomization.
  • Female participants of childbearing and male participants must adhere to the methods.

Exclusion criteria

Exclusion Criteria:

  • Known diagnosis of an IFN-mediated autoinflammatory interferonopathy.
  • History of, or current diagnosis of, non-SLE-related vasculitides.
  • In participants aged 11 years and above: history or evidence of suicidal ideation.
  • History of any non-SLE disease that has required treatment with oral or parenteral for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF.
  • Any positive result on screening for .
  • Active surface antigen OR hepatitis B core antibody (HBcAb), virus (HCV) antibody and detectable HCV ribonucleic acid (RNA) or any active or recent case of Herpes Zoster infection.
  • Any clinical cytomegalovirus or Epstein-Barr virus infection that has not completely resolved within 12 weeks prior to signing the ICF.
  • History of severe COVID-19 infection requiring hospitalization, intensive care unit care, or assisted ventilation or any prior COVID-19 infection with unresolved sequelae. Any mild/asymptomatic COVID-19 infection (laboratory confirmed or suspected based on clinical symptoms).
  • Prior use of anifrolumab.
  • Prior treatment with directly acting cytotoxic B-cell depleting therapeutics (eg, rituximab) \< 26 weeks prior to ICF signature.
  • Blood transfusion or receipt of blood products except albumin within 4 weeks prior to signing the ICF.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Anifrolumab

    Randomized participants will receive anifrolumab via intravenous (IV) infusion every 4 weeks

    Biological: Anifrolumab

  • Placebo comparator
    Placebo

    Randomized participants will receive matching placebo via IV infusion

    Drug: Placebo

Interventions

  • BiologicalAnifrolumab

    Participants will receive anifrolumab via IV infusion.

    Also known as: (MEDI-546)

  • DrugPlacebo

    Participants will receive matching placebo via IV infusion

06

What researchers measure

Primary outcomes

  1. Part A- Anifrolumab serum concentration

    The serum concentration will be characterised and the dose of anifrolumab will be defined in pediatric participants with moderate to severely active SLE.

    Time frame: Pre-dose Day 29

  2. Part A - Maximum observed serum (peak) drug concentration (Cmax)

    The serum PK will be characterised and the dose of anifrolumab will be defined in pediatric participants with moderate to severely active SLE.

    Time frame: Up to Day 29

  3. Part A - Area under the serum concentration curve (AUC)

    The serum PK will be characterised and the dose of anifrolumab will be defined in pediatric participants with moderate to severe active SLE.

    Time frame: Up to Day 29

  4. Part A - Minimum observed serum concentration (Cmin)

    The serum PK will be characterised and the dose of anifrolumab will be defined in pediatric participants with moderate to severe active SLE.

    Time frame: Up to Day 29

  5. Part B - Number of participants who are British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responders (yes/no)

    BICLA response is defined as: * Reduction of all baseline British Isles Lupus Assessment Group BILAG-2004 A to B/C/D and B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥ 1 new BILAG-2004 A or ≥ 2 new BILAG- 2004 B. * No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), defined as an increase from baseline of \> 0 points. * No worsening from baseline in participant's lupus disease activity, defined by an increase ≥ 0.30 points on a Physician's Global Assessment (PGA) 3-point visual analogue scale (VAS).

    Time frame: At Week 52

Secondary outcomes

  1. Part B - Number of participants who are Systemic Lupus Erythematosus Responder Index of ≥ 4 SRI(4) responders (yes/no)

    SRI-4 response is defined as: * ≥ 4-point reduction from baseline in SLEDAI-2K score. * No new organ systems affected as defined by ≥ 1 new BILAG-2004 A or ≥ 2 new BILAG-2004 B items compared to baseline. * No worsening from baseline in participant's lupus disease activity, defined by an increase ≥ 0.30 points on a PGA 3-point VAS.

    Time frame: At Week 52

  2. Part B - Time to first flare

    Time to first flare, where flare is defined as either ≥ 1 new BILAG-2004 A, or ≥ 2 new BILAG-2004 B items compared with the previous visit.

    Time frame: Through Week 52

  3. Part B - Anifrolumab serum concentration

    The PK of anifrolumab in pediatric participants with moderate to severe active SLE will be characterized.

    Time frame: Pre-dose Week 12, Pre-dose Week 24, Pre-dose Week 52

  4. Part - B Change from baseline through Week 52 in antidrug antibody (ADA)

    The immunogenicity of anifrolumab in pediatric participants with moderate to severe active SLE will be characterized.

    Time frame: Up to Week 52

  5. Part - B Change from baseline in anti-double stranded deoxyribonucleic acid antibodies

    The PD of anifrolumab in pediatric participants with moderate to severe active SLE will be characterized.

    Time frame: At Week 12 and Week 52

  6. Part - B Change from baseline in total hemolytic complement (CH50)

    The PD of anifrolumab in pediatric participants with moderate to severe active SLE will be characterized.

    Time frame: At Week 12 and Week 52

  7. Part - B Change from baseline in complement component (C3)

    The PD of anifrolumab in pediatric participants with moderate to severe active SLE will be characterized.

    Time frame: At Week 12 and Week 52

  8. Part - B Change from baseline in complement component (C4)

    The PD of anifrolumab in pediatric participants with moderate to severe active SLE will be characterized.

    Time frame: At Week 12 and Week 52

  9. Number of participants who are Pediatric Rheumatology International Trials Organization/American College of Rheumatology (PRINTO/ACR) childhood-onset systemic lupus erythematosus (cSLE) responders (yes/no)

    PRINTO/ACR cSLE responders are defined as participants with at least 50% improvement from baseline in any 2 of 5 core set outcome measures and no more than one of the remaining worsening more than 30%, where the core set measures are: * ParentGA 21-circle VAS * PGA 3-point VAS * SLEDAI-2K * PedsQL Generic Core (Physical Functioning Domain) * Proteinuria

    Time frame: At Week 52

  10. Part B - The mean percentage reduction from Baseline through Week 52 in oral corticosteroid(s) (OCS) background dose

    The efficacy of anifrolumab vs placebo on OCS background dose in pediatric participants with moderate to severe active SLE will be characterized.

    Time frame: At Week 52

  11. Part B - Change from baseline through Week 52 in type I interferon (IFN) 21-gene signature

    Type 1 IFN 21 gene signatures in pediatric patients with moderate to active SLE will be characterized.

    Time frame: At Week 52

Other outcomes

  1. All parts - Number of participants reporting suicidal ideation and/or suicidal behavior as per Columbia Suicide Severity Rating Scale (C-SSRS)

    The safety and tolerability of anifrolumab in pediatric participants with moderate to severe active SLE will be assessed.

    Time frame: From Week 0 until the follow-up visit (12 weeks post-last dose)

  2. All parts - Number of participants with adverse events

    The safety and tolerability of anifrolumab in pediatric participants with moderate to severe active SLE will be assessed.

    Time frame: From Week 0 until the follow-up visit (12 weeks post-last dose)

07

Study locations

84 of 103 sites recruiting
  • Research Site
    Phoenix, Arizona 85016, United States
    Recruiting
  • Research Site
    Los Angeles, California 90027, United States
    Recruiting
  • Research Site
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60611, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60637, United States
    Recruiting
  • Research Site
    New Orleans, Louisiana 70118, United States
    Recruiting
  • Research Site
    Bethesda, Maryland 20889, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Saint Paul, Minnesota 55125, United States
    Recruiting
  • Research Site
    New Hyde Park, New York 11042, United States
    Recruiting
  • Research Site
    New York, New York 10032, United States
    Recruiting
  • Research Site
    The Bronx, New York 10467, United States
    Recruiting
  • Research Site
    Valhalla, New York 10595, United States
    Recruiting
  • Research Site
    Durham, North Carolina 27710, United States
    Recruiting
  • Research Site
    Cincinnati, Ohio 45229, United States
    Recruiting
  • Research Site
    Cleveland, Ohio 44109, United States
    Recruiting
  • Research Site
    Columbus, Ohio 43203, United States
    Recruiting
  • Research Site
    Portland, Oregon 97227, United States
    Recruiting
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Research Site
    Greenville, South Carolina 29605, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    El Paso, Texas 79902, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Salt Lake City, Utah 84108, United States
    Recruiting
  • Research Site
    Buenos Aires, C1270, Argentina
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Córdoba, 5000, Argentina
    Recruiting
  • Research Site
    Rosario, S2000PBJ, Argentina
    Recruiting
  • Research Site
    San Miguel de Tucumán, T4000AXL, Argentina
    Recruiting
  • Research Site
    Belo Horizonte, 30130-100, Brazil
    Not yet recruiting
  • Research Site
    Belo Horizonte, 30150-274, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90035-903, Brazil
    Recruiting
  • Research Site
    Ribeirão Preto, 14048-900, Brazil
    Recruiting
  • Research Site
    São Paulo, 04024-002, Brazil
    Recruiting
  • Research Site
    São Paulo, 05403 000, Brazil
    Recruiting
  • Research Site
    Calgary, Alberta T2N 4N1, Canada
    Not yet recruiting
  • Research Site
    Vancouver, British Columbia V6H 3N1, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M5G 1X8, Canada
    Recruiting
  • Research Site
    Beijing, 100020, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Beijing, 100032, China
    Not yet recruiting
  • Research Site
    Beijing, 100730, China
    Recruiting
  • Research Site
    Changchun, 130021, China
    Recruiting
  • Research Site
    Changsha, 410007, China
    Recruiting
  • Research Site
    Dongguan, 523059, China
    Not yet recruiting
  • Research Site
    Nanjing, 210008, China
    Recruiting
  • Research Site
    Shanghai, 201102, China
    Recruiting
  • Research Site
    Suzhou, 215002, China
    Recruiting
  • Research Site
    Wenzhou, 325027, China
    Recruiting
  • Research Site
    Zhengzhou, 450018, China
    Recruiting
  • Research Site
    Barranquilla, 01800, Colombia
    Recruiting
  • Research Site
    Medellín, 050034, Colombia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Bordeaux, 33076, France
    Recruiting
  • Research Site
    Bron, 69677, France
    Recruiting
  • Research Site
    Le Kremlin-Bicêtre, 94275, France
    Recruiting
  • Research Site
    Lille, 59037, France
    Recruiting
  • Research Site
    Toulouse, 31300, France
    Recruiting
  • Research Site
    Berlin, D-13353, Germany
    Recruiting
  • Research Site
    Freiburg im Breisgau, 79106, Germany
    Recruiting
  • Research Site
    Sankt Augustin, 53757, Germany
    Recruiting
  • Research Site
    Florence, 50139, Italy
    Not yet recruiting
  • Research Site
    Genova, 16148, Italy
    Recruiting
  • Research Site
    Milan, 20122, Italy
    Recruiting
  • Research Site
    Milan, 20122, Italy
    Not yet recruiting
  • Research Site
    Padova, 35128, Italy
    Recruiting
  • Research Site
    Roma, 00165, Italy
    Recruiting
  • Research Site
    Bunkyō City, 113-8519, Japan
    Recruiting
  • Research Site
    Bunkyō City, 113-8603, Japan
    Recruiting
  • Research Site
    Chiba, 266-0007, Japan
    Recruiting
  • Research Site
    Fuchu-shi, 183-8561, Japan
    Recruiting
  • Research Site
    Kawasaki-shi, 216-8511, Japan
    Recruiting
  • Research Site
    Kobe, 650-0047, Japan
    Recruiting
  • Research Site
    Nagasaki, 852-8501, Japan
    Not yet recruiting
  • Research Site
    Obu-shi, 474-8710, Japan
    Recruiting
  • Research Site
    Shinjuku-ku, 162-8666, Japan
    Recruiting
  • Research Site
    Yokohama, 232 8555, Japan
    Recruiting
  • Research Site
    Yokohama, 236-0004, Japan
    Recruiting
  • Research Site
    Atizapán de Zaragoza, 52937, Mexico
    Not yet recruiting
  • Research Site
    Guadalajara, 44620, Mexico
    Recruiting
  • Research Site
    Mérida, 97070, Mexico
    Recruiting
  • Research Site
    México, 06720, Mexico
    Recruiting
  • Research Site
    Monterrey, 64460, Mexico
    Recruiting
  • Research Site
    Lodź, 91-738, Poland
    Recruiting
  • Research Site
    Warsaw, 02-637, Poland
    Recruiting
  • Research Site
    Wroclaw, 52-114, Poland
    Recruiting
  • Research Site
    Lisbon, 1169-045, Portugal
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Lisbon, 1649-035, Portugal
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Porto, 4200-319, Portugal
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Cape Town, 7700, South Africa
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Esplugues de Llobregat, 8950, Spain
    Recruiting
  • Research Site
    Madrid, 28009, Spain
    Recruiting
  • Research Site
    Madrid, 28034, Spain
    Recruiting
  • Research Site
    Madrid, 28046, Spain
    Recruiting
  • Research Site
    Málaga, 29011, Spain
    Recruiting
  • Research Site
    Santiago de Compostela, 15706, Spain
    Not yet recruiting
  • Research Site
    Valencia, 46026, Spain
    Recruiting
  • Research Site
    Ankara, 06230, Turkey (Türkiye)
    Recruiting
  • Research Site
    Istanbul, 34098, Turkey (Türkiye)
    Recruiting
  • Research Site
    Kayseri, 38039, Turkey (Türkiye)
    Recruiting
  • Research Site
    Umraniye, 34760, Turkey (Türkiye)
    Recruiting
  • Research Site
    Birmingham, B4 6NH, United Kingdom
    Recruiting
  • Research Site
    Bristol, BS2 8BJ, United Kingdom
    Recruiting
  • Research Site
    Liverpool, L12 2AP, United Kingdom
    Recruiting
  • Research Site
    London, NW1 2PG, United Kingdom
    Recruiting

Showing the first 100 of 103 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Oct 2028, 54 months after the start.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 54 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2023
First posted
Apr 28, 2023
StartActual
Mar 14, 2024
Primary completionEst.
Oct 5, 2028
CompletionEst.
Jan 9, 2030
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Research Site · Nanjing, ChinaNot yet recruiting→Recruiting
  • Research Site · Madrid, SpainNot yet recruiting→Recruiting
Show site
  • Research Site · Calgary, Canada
Show 1 removed
  • Research Site · Calgary, Canada
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    1 site added, 1 site removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Research Site · Nanjing, ChinaNot yet recruiting→Recruiting
    • Research Site · Madrid, SpainNot yet recruiting→Recruiting
    Show site
    • Research Site · Calgary, Canada
    Show 1 removed
    • Research Site · Calgary, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05835310
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 28, 2023
Start date
Mar 14, 2024
Primary completion
Oct 5, 2028 (estimated)
Completion
Jan 9, 2030 (estimated)
Last update
Sep 30, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion